What changed
$UNH — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $111.7B | EPS $7.23 vs $6.60 🟢 | Margin 8.1%
💡 The market is pricing UNH at a forward P/E of ~22x on guided $18.25, near the middle of its 5-year range, suggesting skepticism about growth sustainability amid Medicare Advantage headwinds.
📉 Reward/risk: 2.63:1
🏢 Business Quality: 9/10 - Dominant managed care and health services platform, diversified revenue, deep competitive moat, consistent double-digit EPS growth, and high returns on invested capital.
📊 Valuation: fair to slightly cheap — Forward P/E ~22x on guided $18.25 vs. 5-year range 18-24x, but our revised $19.50 estimate implies 20.5x; EV/Sales 0.83x vs.
🔮 Catalyst: Analyst estimate upgrades and first round of 2026 guidance raise typically follow within 4-6 weeks of a strong Q1 beat.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/UNH0620